An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major.

@article{DiavCitrin1999AnII,
  title={An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major.},
  author={O Diav-Citrin and Gardana Atanackovic and Gideon Koren},
  journal={Therapeutic drug monitoring},
  year={1999},
  volume={21 1},
  pages={74-81}
}
Data suggest a large variability in the effectiveness of the orally active iron chelator, deferiprone, in inducing a sustained decrease in body iron to concentrations compatible with the avoidance of complications from iron overload. We analyzed 19 patients with thalassemia major who were undergoing long-term therapy with deferiprone (75 mg/kg/day every 8 hours). In seven of the 19 patients, hepatic iron concentration had been reduced or maintained at less than 7 mg/g of dry weight liver tissue… CONTINUE READING